Alex Drinkall
Menu Access our elearning programmes on the elfh Hub Hub Register / Log in >

Author Archive

Virtual wards enabled by technology: a multidisciplinary elearning programme

Posted on: February 1st, 2022 by Alex Drinkall No Comments

NHS England and Health Education England elearning for healthcare have launched an elearning programme on virtual wards, to support doctors, nurses and allied professionals in the use of technology to provide safe, acute-level care to patients at home. This supports the NHS’s ambition in the 2022/23 NHS planning guidance to increase the number of virtual wards across England.

The elearning is for clinicians to gain an understanding of implementing and running a virtual ward enabled by technology. It should be used alongside organisations’ own local policies. Complete the programme on HEE’s elearning for healthcare platform in around 30 minutes.

If you have any questions about virtual wards more broadly, contact england.virtualward@nhs.net.

Updates made to the COVID-19 vaccination elearning programme

Posted on: January 20th, 2022 by Alex Drinkall No Comments

Since the COVID-19 vaccination programme went live, the content of the different sessions which make up this programme has been updated and amended as more information about the vaccines and the vaccine programme has become available.

For those who have already completed this elearning programme, these updates are detailed below, starting with the most recent.

19 January 2022

All sessions updated to include

17 January 2022

New knowledge and assessment sessions for the Pfizer BioNTech Comirnaty 10 micrograms/dose COVID-19 vaccine added

30 December 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (24/12/21 version)
  • the JCVI recommendations (22/12/21) of booster doses for:
    • all young people aged 16 to 17 years
    • children and young people aged 12 to 15 who are in a clinical risk group or who are a household contact of someone who is immunosuppressed
    • children and young people aged 12 to 17 years who are severely immunocompromised and who have had a third primary dose
  • the JCVI recommendations (22/12/21) that children aged 5 to11 years in a clinical risk group or who are a household contact of someone who is immunosuppressed should be offered COVID-19 vaccination with a lower dose of the Pfizer BioNTech vaccine

17 December 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (14/12/21 version)
  • updates to pregnancy sections following recommendation from JCVI that pregnancy should added to the clinical high risk groups
  • temporary suspension of the requirement for a 15 minute observation period following administration of Pfizer-BioNTech and Moderna COVID-19 vaccines

2 December 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (30/11/21 version)
  • extension of recommendation for booster doses to include all 18- to 39-year-olds
  • change to a 3 month minimum interval between primary course and booster doses
  • recommendation for booster dose from 3 months after third primary dose for those who were severely immunosuppressed at the time of their first or second primary vaccine
  • recommendation for 2nd primary dose for those aged 12 to 15 years

26 November 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (15/11/21 version)
  • extension of recommendation for booster doses to include 40–49-year-olds
  • recommendations for 2nd primary dose for those aged 16 and 17 years

23 September 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (16.9.21 version): notably changes to management of potential contraindications
  • recommendations for booster doses
  • recommendations for 3rd primary dose for those immunosuppressed at the time of their first or second vaccine
  • vaccination recommendations for all 12 to 17 year olds

5 August 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter
  • Guillain-Barré syndrome
  • vaccination recommendations for 12 to 17 year olds

Core session updated to include consent for children and young people

Pfizer BioNTech vaccine session revised to detail transition from use of this vaccine under Regulation 174 to use under Conditional Marketing Authorisation

8 July 2021

Pfizer BioNTech, AstraZeneca and Moderna vaccine sessions all updated to include

  • the latest vaccine effectiveness data
  • reference to JCVI interim advice about a booster vaccination programme
  • myocarditis and pericarditis reports following the Pfizer BioNTech and Moderna vaccines
  • capillary leak syndrome reports following AstraZeneca vaccine
  • revised advice on co-administration and giving COVID-19 vaccine when other vaccines have recently been given
  • advice about mixed vaccine schedules
  • JCVI advice about the recommended interval of 8 to 12 weeks between vaccine doses
  • more information about vaccine induced thrombosis and thrombocytopenia syndrome following AstraZeneca vaccine added and updated contraindications and precautions for this vaccine
  • some minor wording changes to all sessions following recent updates to the Green Book COVID-19 chapter and new web­­links added

11 May 2021

AstraZeneca session updated to include

  • updated advice from the JCVI that an alternative to the AstraZeneca vaccine should be offered to healthy adults aged under 40 years, not only to healthy adults under 30 years as previously recommended in April

21 April 2021

All sessions updated to include

  • new JCVI advice on COVID-19 vaccination for pregnant women

AstraZeneca session more substantially updated to include

  • new advice about very rare blood clotting and unusual bleeding condition following vaccination with AstraZeneca vaccine and the subsequent new contraindications and precautions to this vaccine, including changes to age group recommendations

Some minor wording changes to all sessions following recent updates to the Green Book COVID-19 chapter and new web­­links and images added.

8 April 2021

New knowledge and assessment sessions for the Moderna COVID-19 vaccine added

16 February 2021

Core Knowledge, Pfizer BioNTech and AstraZeneca vaccine sessions all updated to include

  • advice on managing allergic history and allergies after first dose
  • updated information and clarification of advice on vaccination in pregnancy

as stated in revised Green Book COVID-19 chapter

29 January 2021

Pfizer BioNTech vaccine session:

AstraZeneca vaccine session:

  • Change to state multidose vial should be clearly labelled with the date and time of expiry rather than from when it was first punctured

Some minor wording changes in Core Knowledge, Pfizer BioNTech and AstraZeneca sessions in response to user feedback or nationally published guidance.

20 January 2021

Core Knowledge session:

  • Section on Long COVID added,
  • Section on laboratory and pathology staff and social care staff eligibility for vaccination updated to be in line with Green Book COVID-19 chapter
  • Change to wording around immunosuppression to reflect change to Green Book COVID-19 chapter about this

Pfizer BioNTech vaccine session:

  • Waste disposal section updated in response to expert feedback
  • Addition of ordering via Foundry system by PCN designated sites in response to request to add this from Specialist Pharmacy Service (SPS)
  • Change to wording of description of appearance of Pfizer BioNTech vaccine prior to dilution following change about this in the Pfizer Reg174 HCP Information document
  • Addition of link and reference to the Pfizer BioNTech vaccine healthcare professional’s training and information materials (cvdvaccine.co.uk/)

AstraZeneca vaccine session:

  • Waste disposal section updated in response to expert feedback
  • Minor wording changes to “how does the vaccine work” in response to user feedback for clarity
  • Addition of ordering via Foundry system by PCN designated sites in response to request to add this from Specialist Pharmacy Service (SPS)
  • Addition of link and reference to the Pfizer BioNTech vaccine healthcare professional’s training and information materials (cvdvaccine.co.uk/)

8 January 2021

  • Advice about obtaining an additional dose from COVID-19 Vaccine AstraZeneca vials added to AstraZeneca session
  • More information about recommended interval between first and second dose added to both AstraZeneca and Pfizer BioNTech sessions
  • More information added to section about information to provide to recipients following vaccination in both AstraZeneca and Pfizer BioNTech sessions.

31 December 2020

  • New knowledge and assessment sessions on the AstraZeneca COVID-19 vaccine added
  • Core Knowledge and Pfizer BioNTech vaccine sessions updated to include: revised advice from JCVI on pregnancy and breastfeeding, updated statement from JCVI about scheduling of vaccine doses (between 4 and 12 weeks),
  • Pfizer BioNTech session updated to include: advice on obtaining a 6th dose from a vial, and allergy precautions as stated in updated Green Book COVID-19 chapter and updated Information for Healthcare Professionals on Pfizer BioNTech COVID-19 vaccine document

December 2020

  • Core Knowledge session updated with advice about not giving COVID-19 vaccine to pregnant or breastfeeding women after the COVID-19 mRNA Vaccine BNT162b2 (Pfizer BioNTech) was authorised for use
  • New MHRA guidance added on not giving COVID-19 mRNA Vaccine BNT162b2 to those with a history of anaphylaxis to a vaccine, medicine or food or a previous dose of the vaccine and addition of 15 minute minimum observation period following vaccination
  • Some amendments to the COVID-19 mRNA Vaccine BNT162b2 session storage and reconstitution sections following republication of updated Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine document

Updates made to the COVID-19 vaccination elearning programme

Posted on: January 11th, 2022 by Alex Drinkall No Comments

Since the COVID-19 vaccination programme went live, the content of the different sessions which make up this programme has been updated and amended as more information about the vaccines and the vaccine programme has become available.

For those who have already completed this elearning programme, these updates are detailed below, starting with the most recent.

30 December 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (24/12/21 version)
  • the JCVI recommendations (22/12/21) of booster doses for:
    • all young people aged 16 to 17 years
    • children and young people aged 12 to 15 who are in a clinical risk group or who are a household contact of someone who is immunosuppressed
    • children and young people aged 12 to 17 years who are severely immunocompromised and who have had a third primary dose
  • the JCVI recommendations (22/12/21) that children aged 5 to11 years in a clinical risk group or who are a household contact of someone who is immunosuppressed should be offered COVID-19 vaccination with a lower dose of the Pfizer BioNTech vaccine

17 December 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (14/12/21 version)
  • updates to pregnancy sections following recommendation from JCVI that pregnancy should added to the clinical high risk groups
  • temporary suspension of the requirement for a 15 minute observation period following administration of Pfizer-BioNTech and Moderna COVID-19 vaccines

2 December 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (30/11/21 version)
  • extension of recommendation for booster doses to include all 18- to 39-year-olds
  • change to a 3 month minimum interval between primary course and booster doses
  • recommendation for booster dose from 3 months after third primary dose for those who were severely immunosuppressed at the time of their first or second primary vaccine
  • recommendation for 2nd primary dose for those aged 12 to 15 years

26 November 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (15/11/21 version)
  • extension of recommendation for booster doses to include 40–49-year-olds
  • recommendations for 2nd primary dose for those aged 16 and 17 years

23 September 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (16.9.21 version): notably changes to management of potential contraindications
  • recommendations for booster doses
  • recommendations for 3rd primary dose for those immunosuppressed at the time of their first or second vaccine
  • vaccination recommendations for all 12 to 17 year olds

5 August 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter
  • Guillain-Barré syndrome
  • vaccination recommendations for 12 to 17 year olds

Core session updated to include consent for children and young people

Pfizer BioNTech vaccine session revised to detail transition from use of this vaccine under Regulation 174 to use under Conditional Marketing Authorisation

8 July 2021

Pfizer BioNTech, AstraZeneca and Moderna vaccine sessions all updated to include

  • the latest vaccine effectiveness data
  • reference to JCVI interim advice about a booster vaccination programme
  • myocarditis and pericarditis reports following the Pfizer BioNTech and Moderna vaccines
  • capillary leak syndrome reports following AstraZeneca vaccine
  • revised advice on co-administration and giving COVID-19 vaccine when other vaccines have recently been given
  • advice about mixed vaccine schedules
  • JCVI advice about the recommended interval of 8 to 12 weeks between vaccine doses
  • more information about vaccine induced thrombosis and thrombocytopenia syndrome following AstraZeneca vaccine added and updated contraindications and precautions for this vaccine
  • some minor wording changes to all sessions following recent updates to the Green Book COVID-19 chapter and new web­­links added

11 May 2021

AstraZeneca session updated to include

  • updated advice from the JCVI that an alternative to the AstraZeneca vaccine should be offered to healthy adults aged under 40 years, not only to healthy adults under 30 years as previously recommended in April

21 April 2021

All sessions updated to include

  • new JCVI advice on COVID-19 vaccination for pregnant women

AstraZeneca session more substantially updated to include

  • new advice about very rare blood clotting and unusual bleeding condition following vaccination with AstraZeneca vaccine and the subsequent new contraindications and precautions to this vaccine, including changes to age group recommendations

Some minor wording changes to all sessions following recent updates to the Green Book COVID-19 chapter and new web­­links and images added.

8 April 2021

New knowledge and assessment sessions for the Moderna COVID-19 vaccine added

16 February 2021

Core Knowledge, Pfizer BioNTech and AstraZeneca vaccine sessions all updated to include

  • advice on managing allergic history and allergies after first dose
  • updated information and clarification of advice on vaccination in pregnancy

as stated in revised Green Book COVID-19 chapter

29 January 2021

Pfizer BioNTech vaccine session:

AstraZeneca vaccine session:

  • Change to state multidose vial should be clearly labelled with the date and time of expiry rather than from when it was first punctured

Some minor wording changes in Core Knowledge, Pfizer BioNTech and AstraZeneca sessions in response to user feedback or nationally published guidance.

20 January 2021

Core Knowledge session:

  • Section on Long COVID added,
  • Section on laboratory and pathology staff and social care staff eligibility for vaccination updated to be in line with Green Book COVID-19 chapter
  • Change to wording around immunosuppression to reflect change to Green Book COVID-19 chapter about this

Pfizer BioNTech vaccine session:

  • Waste disposal section updated in response to expert feedback
  • Addition of ordering via Foundry system by PCN designated sites in response to request to add this from Specialist Pharmacy Service (SPS)
  • Change to wording of description of appearance of Pfizer BioNTech vaccine prior to dilution following change about this in the Pfizer Reg174 HCP Information document
  • Addition of link and reference to the Pfizer BioNTech vaccine healthcare professional’s training and information materials (cvdvaccine.co.uk/)

AstraZeneca vaccine session:

  • Waste disposal section updated in response to expert feedback
  • Minor wording changes to “how does the vaccine work” in response to user feedback for clarity
  • Addition of ordering via Foundry system by PCN designated sites in response to request to add this from Specialist Pharmacy Service (SPS)
  • Addition of link and reference to the Pfizer BioNTech vaccine healthcare professional’s training and information materials (cvdvaccine.co.uk/)

8 January 2021

  • Advice about obtaining an additional dose from COVID-19 Vaccine AstraZeneca vials added to AstraZeneca session
  • More information about recommended interval between first and second dose added to both AstraZeneca and Pfizer BioNTech sessions
  • More information added to section about information to provide to recipients following vaccination in both AstraZeneca and Pfizer BioNTech sessions.

31 December 2020

  • New knowledge and assessment sessions on the AstraZeneca COVID-19 vaccine added
  • Core Knowledge and Pfizer BioNTech vaccine sessions updated to include: revised advice from JCVI on pregnancy and breastfeeding, updated statement from JCVI about scheduling of vaccine doses (between 4 and 12 weeks),
  • Pfizer BioNTech session updated to include: advice on obtaining a 6th dose from a vial, and allergy precautions as stated in updated Green Book COVID-19 chapter and updated Information for Healthcare Professionals on Pfizer BioNTech COVID-19 vaccine document

December 2020

  • Core Knowledge session updated with advice about not giving COVID-19 vaccine to pregnant or breastfeeding women after the COVID-19 mRNA Vaccine BNT162b2 (Pfizer BioNTech) was authorised for use
  • New MHRA guidance added on not giving COVID-19 mRNA Vaccine BNT162b2 to those with a history of anaphylaxis to a vaccine, medicine or food or a previous dose of the vaccine and addition of 15 minute minimum observation period following vaccination
  • Some amendments to the COVID-19 mRNA Vaccine BNT162b2 session storage and reconstitution sections following republication of updated Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine document

Updates made to the COVID-19 vaccination elearning programme

Posted on: December 7th, 2021 by Alex Drinkall No Comments

Since the COVID-19 vaccination programme went live, the content of the different sessions which make up this programme has been updated and amended as more information about the vaccines and the vaccine programme has become available.

For those who have already completed this elearning programme, these updates are detailed below, starting with the most recent.

10 March 2022

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (28/02/22 version)
  • information about the about Spring booster and vaccination programme for all 5 to 11 years olds

Link: https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a

19 January 2022

All sessions updated to include

Link: https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a

17 January 2022

New knowledge and assessment sessions for the Pfizer BioNTech Comirnaty 10 micrograms/dose COVID-19 vaccine added

30 December 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (24/12/21 version)
  • the JCVI recommendations (22/12/21) of booster doses for:
    • all young people aged 16 to 17 years
    • children and young people aged 12 to 15 who are in a clinical risk group or who are a household contact of someone who is immunosuppressed
    • children and young people aged 12 to 17 years who are severely immunocompromised and who have had a third primary dose
  • the JCVI recommendations (22/12/21) that children aged 5 to11 years in a clinical risk group or who are a household contact of someone who is immunosuppressed should be offered COVID-19 vaccination with a lower dose of the Pfizer BioNTech vaccine

Link: https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a

17 December 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (14/12/21 version)
  • updates to pregnancy sections following recommendation from JCVI that pregnancy should added to the clinical high risk groups
  • temporary suspension of the requirement for a 15 minute observation period following administration of Pfizer-BioNTech and Moderna COVID-19 vaccines 

Link: https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a

2 December 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (30/11/21 version)
  • extension of recommendation for booster doses to include all 18- to 39-year-olds
  • change to a 3 month minimum interval between primary course and booster doses
  • recommendation for booster dose from 3 months after third primary dose for those who were severely immunosuppressed at the time of their first or second primary vaccine
  • recommendation for 2nd primary dose for those aged 12 to 15 years

26 November 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (15/11/21 version)
  • extension of recommendation for booster doses to include 40–49-year-olds
  • recommendations for 2nd primary dose for those aged 16 and 17 years

23 September 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter (16.9.21 version): notably changes to management of potential contraindications
  • recommendations for booster doses
  • recommendations for 3rd primary dose for those immunosuppressed at the time of their first or second vaccine
  • vaccination recommendations for all 12 to 17 year olds

 5 August 2021

All sessions updated to include

  • revisions following republication of the Green Book COVID-19 Chapter
  • Guillain-Barré syndrome
  • vaccination recommendations for 12 to 17 year olds

Core session updated to include consent for children and young people

Pfizer BioNTech vaccine session revised to detail transition from use of this vaccine under Regulation 174 to use under Conditional Marketing Authorisation

8 July 2021

Pfizer BioNTech, AstraZeneca and Moderna vaccine sessions all updated to include

  • the latest vaccine effectiveness data
  • reference to JCVI interim advice about a booster vaccination programme
  • myocarditis and pericarditis reports following the Pfizer BioNTech and Moderna vaccines
  • capillary leak syndrome reports following AstraZeneca vaccine
  • revised advice on co-administration and giving COVID-19 vaccine when other vaccines have recently been given
  • advice about mixed vaccine schedules
  • JCVI advice about the recommended interval of 8 to 12 weeks between vaccine doses
  • more information about vaccine induced thrombosis and thrombocytopenia syndrome following AstraZeneca vaccine added and updated contraindications and precautions for this vaccine
  • some minor wording changes to all sessions following recent updates to the Green Book COVID-19 chapter and new web­­links added

 11 May 2021

AstraZeneca session updated to include

  • updated advice from the JCVI that an alternative to the AstraZeneca vaccine should be offered to healthy adults aged under 40 years, not only to healthy adults under 30 years as previously recommended in April

21 April 2021

All sessions updated to include

  • new JCVI advice on COVID-19 vaccination for pregnant women

AstraZeneca session more substantially updated to include

  • new advice about very rare blood clotting and unusual bleeding condition following vaccination with AstraZeneca vaccine and the subsequent new contraindications and precautions to this vaccine, including changes to age group recommendations

Some minor wording changes to all sessions following recent updates to the Green Book COVID-19 chapter and new web­­links and images added.

8 April 2021

New knowledge and assessment sessions for the Moderna COVID-19 vaccine added

 16 February 2021

Core Knowledge, Pfizer BioNTech and AstraZeneca vaccine sessions all updated to include

  • advice on managing allergic history and allergies after first dose
  • updated information and clarification of advice on vaccination in pregnancy

as stated in revised Green Book COVID-19 chapter

29 January 2021

Pfizer BioNTech vaccine session:

AstraZeneca vaccine session:

  • Change to state multidose vial should be clearly labelled with the date and time of expiry rather than from when it was first punctured

Some minor wording changes in Core Knowledge, Pfizer BioNTech and AstraZeneca sessions in response to user feedback or nationally published guidance.

 20 January 2021

Core Knowledge session:

  • Section on Long COVID added,
  • Section on laboratory and pathology staff and social care staff eligibility for vaccination updated to be in line with Green Book COVID-19 chapter
  • Change to wording around immunosuppression to reflect change to Green Book COVID-19 chapter about this

Pfizer BioNTech vaccine session:

  • Waste disposal section updated in response to expert feedback
  • Addition of ordering via Foundry system by PCN designated sites in response to request to add this from Specialist Pharmacy Service (SPS)
  • Change to wording of description of appearance of Pfizer BioNTech vaccine prior to dilution following change about this in the Pfizer Reg174 HCP Information document
  • Addition of link and reference to the Pfizer BioNTech vaccine healthcare professional’s training and information materials (cvdvaccine.co.uk/)

AstraZeneca vaccine session:

  • Waste disposal section updated in response to expert feedback
  • Minor wording changes to “how does the vaccine work” in response to user feedback for clarity
  • Addition of ordering via Foundry system by PCN designated sites in response to request to add this from Specialist Pharmacy Service (SPS)
  • Addition of link and reference to the Pfizer BioNTech vaccine healthcare professional’s training and information materials (cvdvaccine.co.uk/)

8 January 2021

  • Advice about obtaining an additional dose from COVID-19 Vaccine AstraZeneca vials added to AstraZeneca session
  • More information about recommended interval between first and second dose added to both AstraZeneca and Pfizer BioNTech sessions
  • More information added to section about information to provide to recipients following vaccination in both AstraZeneca and Pfizer BioNTech sessions.

31 December 2020

  • New knowledge and assessment sessions on the AstraZeneca COVID-19 vaccine added
  • Core Knowledge and Pfizer BioNTech vaccine sessions updated to include: revised advice from JCVI on pregnancy and breastfeeding, updated statement from JCVI about scheduling of vaccine doses (between 4 and 12 weeks),
  • Pfizer BioNTech session updated to include: advice on obtaining a 6th dose from a vial, and allergy precautions as stated in updated Green Book COVID-19 chapter and updated Information for Healthcare Professionals on Pfizer BioNTech COVID-19 vaccine document

December 2020

  • Core Knowledge session updated with advice about not giving COVID-19 vaccine to pregnant or breastfeeding women after the COVID-19 mRNA Vaccine BNT162b2 (Pfizer BioNTech) was authorised for use
  • New MHRA guidance added on not giving COVID-19 mRNA Vaccine BNT162b2 to those with a history of anaphylaxis to a vaccine, medicine or food or a previous dose of the vaccine and addition of 15 minute minimum observation period following vaccination
  • Some amendments to the COVID-19 mRNA Vaccine BNT162b2 session storage and reconstitution sections following republication of updated Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine document.

HEE’s TEL team scoop award for COVID-19 vaccination work

Posted on: November 30th, 2021 by Alex Drinkall No Comments

Health Education England’s elearning for healthcare (elfh) team won the Digital Transformation award at last week’s GovNews Direct Smarter Working Live Awards for their work on the COVID-19 vaccination elearning programme.

The team, in partnership with the UK Health Security Agency (formerly Public Health England) and NHS England and NHS Improvement developed the core digital theory training for all COVID-19 vaccinators in England.

Every vaccinator in England has completed the elfh COVID-19 vaccination elearning programme meaning the resource has played a fundamental role in the success of the roll out of the vaccination programme.  To date there have been more than 2.7million session launches of the elearning programme.

Dr Neil Ralph, Head of Technology Enhanced Learning, Health Education England said: “I am absolutely delighted that the team’s work has been recognised for its contribution to the COVID-19 response.  They worked tirelessly to ensure the COVID-19 vaccination programme was the best it could be, in a very short time frame and is testament to the expertise, passion and commitment we have in the elearning for healthcare team.”

For more information about elfh visit www.e-lfh.org.uk.

New elearning programme on the role of the Caldicott Guardian now available

Posted on: November 24th, 2021 by Alex Drinkall No Comments

Health Education England elearning for healthcare (HEE elfh) has worked in partnership with the National Data Guardian and the UK Caldicott Guardian Council to develop a new elearning programme for Caldicott Guardians, and those with an interest in finding out more about the role Caldicott Guardians play in keeping people’s health and social care data safe, and ensuring it is used appropriately.

The aim of this elearning session “sharing information and protecting confidentiality in health and care” is to raise awareness and inform a broad range of staff from across health and social care of the importance of Caldicott Guardians and confidentiality in their setting, organisation, or sector. The learning is for staff working in the NHS, adult social care, local authorities and private sector partners.

Two additional sessions, one for new or existing Caldicott Guardians and one for senior staff who may need to appoint or support a Caldicott Guardian will be available soon.

In August 2021, the National Data Guardian published guidance about the appointment, role and responsibilities of Caldicott Guardians. It introduced a formal requirement that increases the type and number of organisations who need to appoint a Caldicott Guardian. This elearning is intended to support those implementing the guidance who may need to understand more about the role. Read more about the NDG guidance and who it applies to.

For more information about the Role of the Caldicott Guardian elearning programme, including details on how to access the free resource, visit the HEE elearning for healthcare website.

Late career AHPs supporting practice based learning resource now live

Posted on: November 2nd, 2021 by Alex Drinkall No Comments

Health Education England elearning for healthcare has worked in partnership with the Health and Care Professions Council and NHS England and NHS Improvement to develop a new elearning programme to provide allied health professionals (AHPs) in their late career with information so they can consider the options that are available to them, rather than leaving the NHS completely.

The resources are also suitable for individuals who have already retired and who may no longer be registered with the Health and Care Professions Council.

To grow and deliver an AHP workforce that meets the ambitions set out in the NHS People Plan and Long Term Plan, it is essential the knowledge and skills of our late career AHPs are harnessed and provide the opportunity for individuals to leave their legacy.

The programme is made up of two sessions, each taking around 45 minutes to complete with additional activities and resources available for learners.
For more information about the elearning programme, including details on how to access the free resource, visit the elfh website.

New patient safety training materials launched

Posted on: October 28th, 2021 by Alex Drinkall No Comments

New patient safety training materials have been published by Health Education England, NHS England and NHS Improvement, The Academy of Medical Royal Colleges and elearning for healthcare, elements of which are expected to be completed by NHS employees, even those in roles which are not patient facing. Completion of the training will help to ensure health and care services are as safe as possible for patients and service users.

The training materials can be found on the elearning for healthcare hub. The training has five levels, which build on each other, the first two levels Essentials for patient safety and Access to practice being made available today. The first level, Essentials for patient safety, is the starting point and all NHS staff are encouraged to complete it. Level two, Access to practice is intended for those who have an interest in understanding more about patient safety and those who want to go on to access the higher levels of training.

The training has been devised following the publication of the NHS Patient Safety Strategy which contains a patient safety syllabus. The syllabus sets out a new approach to patient safety emphasising a proactive approach to identifying risks to safe care while also including systems thinking and human factors, all of which has been incorporated into the training.

Levels three to five of the training are expected to be available by the end of March 2022

elfh is a Health Education England programme in partnership with the NHS and professional bodies